Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Britain Courts Anthropic Amid US Defense Department Dispute 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NEW YORK, Nov. 14, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”) has filed an action in the United States District Court – Western District of Kentucky against Humana, Inc. and Humana Pharmacy Solutions, Inc. (collectively, “Humana” or “Defendants”).
Defendants are health insurance companies along with pharmacy benefit managers (“PBMs”). The PBMs are retained by the health insurance companies, on behalf of the plan or third-party payors, to provide the pharmacy benefits to plan members, which includes, inter alia, establishing a formulary of drugs that will be covered, a network of pharmacies that will serve as participating pharmacies for plan participants to obtain their prescriptions, copayment amounts, coinsurance amounts, and deductibles.
Specifically, the action relates to Defendants engaging in a scheme to defraud plan members by artificially inflating the copayment of medically necessary prescription drugs well above the cost of the drug. Plan participants, including Plaintiff and the Class, pay inflated copayments to participating pharmacies in exchange for receiving their prescription drugs. Unbeknownst to the plan participants, Defendants artificially inflate the purported costs of the prescription drugs in the form of increased copayments and then “claw back,” or recoup, from the pharmacies a large portion of the copayments.
Class members are consumers who pay artificially inflated copayments for medically necessary, covered prescriptions that cost plan participants more than if they did not have insurance. If you would like addition information, please contact Michael Burnett of Scott+Scott ([email protected], (800) 404-7770, (860) 537-5537).
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]
